COVID-19 Analytics

Real-time Patient Safety Indicators and Visit Forecasting for Proactive Oversight of the COVID-19 Pandemic Impact on Your Clinical Trials

COVID-19 Analytics

Real-time Patient Safety Indicators and Visit Forecasting for Proactive Oversight of the COVID-19 Pandemic Impact on Your Clinical Trials

Manage Risk, Mitigate Impact

eClinical Solutions has developed elluminate^® COVID-19 Analytics based on industry and client feedback to help sponsors manage the impact of COVID-19 on their ongoing trials.

These analytics provide trial managers with the real-time clinical and operational insights needed to proactively manage the impact of COVID-19 on patient safety and data quality. elluminate COVID-19 Analytics will also help increase oversight and regulatory compliance with recommendations made in the recent FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic.

Proactively Mitigates COVID-19 Risks on Your Trials
Improves Oversight and Regulatory Compliance
Can be Rapidly Implemented for Ongoing Trials

Your Experienced Partner for Program-Level Data Strategy

Visualizations show you which patients and sites have the highest virus-related indicator scores, and visit forecasts allow you to focus your time where it is needed most, first. Filtering includes subject populations at-risk, based on age range and immunocompromised status.

elluminate COVID-19 Analytics Standard Visualizations include:

Visit and Dose Trends & Forecasts
Visit and Dose Cumulative
COVID Indicators
Off Study and Disposition
Adverse Events

elluminate COVID-19 Analytics

elluminate COVID-19 analytics are designed to answer your questions around COVID-19 study impacts with dashboard summaries, key indicators and data visualization insights. Brought to you by eClinical Solutions using the industry-leading elluminate clinical data cloud, this set of COVID-19 analytics is just one part of a complete cloud-based enterprise software platform that makes data acquisition, mapping, and analysis easy – so you can focus on the story you find in the data.

Introducing elluminate COVID-19 Analytics Webinar

Recorded Live: April 8, 2020

Vice President of Product Management and clinical data strategy expert Robert Musterer share the benefits of elluminate COVID-19 Analytics and demonstrates the out-the-box visualizations in this live 1-hour webcast. You will learn more about this offering and best practices for effectively using analytics and the elluminate Clinical Data Hub to mitigate COVID-19 associated risk.

Which patients have missed visits that may require “…specific information in the case report form that explains the basis of the missing data, including the relationship to COVID-19 for missing protocol-specified information (e.g., from missed study visits or study discontinuations due to COVID-19).

Trial participants may not be able to come to the investigational site for protocol-specified visits,” allowing sponsors to evaluate “whether alternative methods for safety assessments (e.g., phone contact, virtual visit, alternative location for assessment, including local labs or imaging centers) could be implemented when necessary and feasible

Trial participants who no longer have access to investigational product or the investigational site may need additional safety monitoring (e.g. withdrawal of an active investigational treatment)...

Resources

eClinical Solutions COVID-19 Resources

More than 50 Life Sciences companies rely on Clinical Analytics from elluminate to improve the clinical data review process and enhance operational oversight.

Webinar: Introducing elluminate COVID-19 Analytics

Learn more

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic

Learn more

Blog: How Groundhog Day Inspired COVID-19 Clinical Trial Analytics

Learn more

Get the Facts

Learn more

April 7, 2019 Press Release: eClinical Solutions Delivers elluminate COVID-19 Clinical Trial Analytics

Learn more

Live 30-min Webinar: Intro to elluminate

Learn more

COVID-19: Developing Drugs and Biological Products for Treatment or Prevention

Learn more

Visualizations

Robust filtering to research subject populations such as those at risk based on age range and immunocompromised status.

Visit and Dose Trends & Forecasts

Visit-related visualizations provide details on missed and overdue visits, missed and overdue doses, counts of forecasted visits by month, and the visit timelines by subject.

COVID Indicators

A broad set of terms are evaluated for reported symptoms, listed by the CDC, as indicative of COVID-19.

Resultant site and participant level indicator scores provide a mechanism for prioritizing efforts.

Visit and Dose Cumulations

Study level views of cumulative visits and doses.

Illustrate the cumulative impact of missed visits and doses overtime. Pie Chart indicates % expected, administered, overdue and missed doses and visits.

Filter by country, study, site, subject.

Off Study & Disposition

Visualizations highlight reasons for withdrawal to assist in evaluating impact on study participant numbers.

Adverse Events

Displays counts of adverse events by subject and events at the level of system organ class or preferred term.

Filter by study, site, subject, treatment, severity.

COVID-19 Analytics

COVID-19 Analytics

Manage Risk, Mitigate Impact

Your Experienced Partner for Program-Level Data Strategy

elluminate COVID-19 Analytics

Introducing elluminate COVID-19 Analytics Webinar

eClinical Solutions COVID-19 Resources

Webinar: Introducing elluminate COVID-19 Analytics

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic

Blog: How Groundhog Day Inspired COVID-19 Clinical Trial Analytics

Get the Facts

April 7, 2019 Press Release: eClinical Solutions Delivers elluminate COVID-19 Clinical Trial Analytics

Live 30-min Webinar: Intro to elluminate

​COVID-19: Developing Drugs and Biological Products for Treatment or Prevention

Visualizations

Visit and Dose Trends & Forecasts

COVID Indicators

Visit and Dose Cumulations

Off Study & Disposition

Adverse Events

COVID-19: Developing Drugs and Biological Products for Treatment or Prevention